These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9699230)

  • 1. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.
    Thall PF; Sung HG
    Stat Med; 1998 Jul; 17(14):1563-80. PubMed ID: 9699230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
    Thall PF; Estey EH
    Stat Med; 1993 Jul; 12(13):1197-211. PubMed ID: 8210822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new program to compute and evaluate continuously monitored stopping boundaries for clinical trials.
    Lazaridis E; Gonin R
    Comput Methods Programs Biomed; 2000 Mar; 61(3):187-94. PubMed ID: 10710181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
    Thall PF; Russell KE
    Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.
    Jiang W; Wick JA; He J; Mahnken JD; Mayo MS
    J Biopharm Stat; 2018; 28(5):824-839. PubMed ID: 29172970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials.
    He J; Entsuah R
    Pharm Stat; 2014; 13(5):327-36. PubMed ID: 25182571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.
    Morita S; Sakamoto J
    Pharm Stat; 2006; 5(2):109-18. PubMed ID: 17080767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.